Quanta Inc (fka QNTA)

[JediMozart]

Over 16 years of research … so, the way I see it, a couple months of delay after 16 years of research and strategic mergers culminating together is negligible.. especially if one is invested in the company … medicinal items, if taken seriously by the globe, are held to high standards of testing & substantiated data…. Some are frustrated they didn’t make money over night here … IMO this stock is an investment not a flip .. I’m long and holding and impressed by the diligent research and steps made to get them to the position they are in now …
- - - - - - - - QNTA - - - - - - - -
“The founder of Medolife, Dr. Arthur Grant Mikaelian, started his independent investigation in 2004 related to the Caribbean Blue Scorpion. Scientific data, which was available at the time, made him believe that the scorpion venom had potential therapeutic values. He was sure it could be a valuable organic compound when combined with his polarization technology.”
- - - -
Worth noting … research and development of anything “pharmaceutical” related takes time …
- - - - -
“Upon product registration in the DR, Medolife estimates demand for Escozine® could be upwards of one million doses in the first quarter after registration. The Company is actively scaling up cultivation of the peptide in order to meet this demand, as well as planning an additional expansion to the reservation in the form of a medical lab facility on the premises, which would decrease logistical costs in the Escozine® production process. Beyond its pending product registration in the DR, data on Escozine® has been submitted to the US Food and Drug Administration (FDA) through the Investigational New Drug regulatory pathway, which, if approved, would make Escozine® available to patients in the US in a matter of months.

“With a gallon of scorpion venom costing upwards of $39 million, expanding our own cultivation reservation in order to meet our internal demand for the peptides used in Escozine only made further sense,” said Medolife CEO Dr. Arthur Mikaelian. “We have one of the largest scorpion reservations in the world and this expansion only further solidifies that position. As we await our pending regulatory approvals, which we expect in short order starting within the DR, we must prepare to meet the immediate demand the approvals will render by increasing our scorpion cultivation efforts. While we plan to focus first on the Rhopalurus princeps, which is one of several types of Blue Scorpions, the expansion will also allow us to add other scorpions such as Rhopalurus abudi, whose venom has seen promising results in treating various cancers. Our next step of adding a lab facility to the location is imminent, and we will be able to fully integrate our supply chain of Escozine® and further position Medolife as an integrated global pharmaceutical and nutraceutical company.”
- - - - - -
GLTA :~$) paytience .. IMO will pay

https://medolife.com/history/

https://www.globenewswire.com/en/news-release/2021/03/30/2201650/0/en/Medolife-Rx-Furthers-Expansion-of-Scorpion-Reservation-Prepares-for-Mass-Production-of-Escozine-Required-Upon-Product-Registration.html